文献速递急性肾损伤慢性肾脏病水电解质与酸碱

SGLT-2抑制剂对2型糖尿病患者术后急性肾损伤的保护作用

The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes.
PubMed 文献 · Kidney Int Rep · 2025-06-25

该回顾性研究纳入2013至2023年韩国某三级医院接受大手术的糖尿病患者5527例,比较术前使用SGLT-2抑制剂与DPP-4抑制剂者术后7天内急性肾损伤的发生情况。倾向评分匹配后,SGLT-2i组术后AKI发生率为11.9%,DPP-4i组为15.1%(P=0.026),多因素分析显示SGLT-2i使用与术后AKI风险降低31%相关(OR 0.699,95%CI 0.528-0.918,P=0.011)。SGLT-2i组轻度糖尿病酮症酸中毒发生率高于DPP-4i组(0.8% vs 0%,P<0.001)。

要点

  • 匹配队列中SGLT-2i组术后AKI发生率11.9%,DPP-4i组15.1%(P=0.026)。
  • SGLT-2i使用与术后AKI风险降低31%独立相关(OR 0.699,95%CI 0.528-0.918)。
  • 心衰接受心血管手术者AKI发生率增至54%,SGLT-2i使风险降低57%(OR 0.431,95%CI 0.205-0.889)。

核心结论

  • 在2型糖尿病患者中,SGLT-2i使用与术后AKI风险低于DPP-4i独立相关,尤其在心衰接受心血管手术的高危人群中。
  • 作者认为SGLT-2i可能在糖尿病患者围术期AKI预防中发挥作用,但建议仔细监测DKA。

研究设计与样本

  • 回顾性研究,纳入2013至2023年韩国某三级医院接受大手术的糖尿病患者5527例。
  • 比较术前使用SGLT-2i与DPP-4i者术后7天内AKI发生情况,采用1:3倾向评分匹配调整10个潜在混杂因素。

主要发现

  • 匹配前平均年龄67.5岁,男性占66.3%。
  • 匹配队列中术后AKI发生率SGLT-2i组11.9% vs DPP-4i组15.1%(P=0.026)。
  • 多因素logistic回归显示SGLT-2i使用与术后AKI风险降低31%相关(OR 0.699,95%CI 0.528-0.918,P=0.011)。
  • 心衰接受心血管手术者AKI发生率增至54%,SGLT-2i使AKI风险降低57%(OR 0.431,95%CI 0.205-0.889,P=0.024)。
  • SGLT-2i组轻度DKA发生率高于DPP-4i组(0.8% vs 0%,P<0.001)。

临床怎么用

  • 作者认为SGLT-2i可能在糖尿病患者围术期AKI预防中发挥作用,同时建议仔细监测DKA。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite concerns about the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) to cause acute kidney injury (AKI), recent studies have shown that patients with diabetes on long-term SGLT-2i have lower rates of AKI-related hospitalizations and dialysis. We aimed to assess the real-world preventive effects of SGLT-2i on the risk of postoperative AKI. METHODS: We conducted a retrospective study on patients with diabetes who underwent a major surgery at a tertiary hospital in Korea from 2013 to 2023 (n = 5527). We compared patients receiving SGLT-2i with those receiving dipeptidyl peptidase-4 inhibitors (DPP-4i) before surgery to evaluate the development of AKI within 7 days after surgery. A 1:3 propensity score matching was performed to adjust for 10 potential confounders. RESULTS: Before matching, the mean age was 67.5 years, with males comprising 66.3% of the cohort. In the matched cohort, the incidence of postoperative AKI was 11.9% in patients on SGLT-2i and 15.1% in those on DPP-4i (P = 0.026). In a multivariable logistic regression analysis adjusted for various risk factors, the use of SGLT-2i was associated with a 31% reduction in the risk of postoperative AKI (odds ratio [OR]: 0.699; 95% confidence interval [CI]: 0.528-0.918; P = 0.011). Subgroup analyses demonstrated a significant protective effect of SGLT-2i in high-risk populations, particularly in patients with heart failure undergoing cardiovascular surgery, where the incidence of AKI increased to 54%, in which SGLT-2i reduced the risk of AKI by up to 57% (OR: 0.431; 95% CI: 0.205-0.889; P = 0.024). However, the SGLT-2i group experienced a higher incidence of mild diabetic ketoacidosis (DKA) than the DPP-4i group (0.8% vs. 0%; P < 0.001). CONCLUSION: The use of SGLT-2i was independently associated with a lower risk of postoperative AKI than the use of DPP-4i in patients with type 2 diabetes, particularly in high-risk groups such as those with heart failure undergoing cardiovascular surgery. These findings suggest that SGLT-2i may have a role in perioperative AKI prevention in patients with diabetes, although careful monitoring for DKA is advised.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Song SM, Kim M, Jang M, et al. The Protective Effects of SGLT-2 Inhibitors Against Postoperative Acute Kidney Injury in Type 2 Diabetes. Kidney Int Rep. 2025. PMID: 40980648. doi:10.1016/j.ekir.2025.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。